Inhibikase Therapeutics, Inc.
IKT
$1.67
-$0.01-0.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -279.57% | -- | -74.22% | -100.85% | -117.00% |
| Gross Profit | 279.57% | -- | 74.22% | 100.86% | 117.25% |
| SG&A Expenses | 75.94% | 107.01% | 219.64% | 163.78% | 113.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.41% | 59.47% | 163.08% | 137.63% | 94.41% |
| Operating Income | -21.41% | -59.47% | -163.08% | -138.62% | -96.30% |
| Income Before Tax | -39.43% | -75.36% | -143.58% | -125.79% | -90.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.43% | -75.36% | -143.58% | -125.79% | -90.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.43% | -75.36% | -143.58% | -125.79% | -90.35% |
| EBIT | -21.41% | -59.47% | -163.08% | -138.62% | -96.30% |
| EBITDA | -21.35% | -59.40% | -163.09% | -138.69% | -97.90% |
| EPS Basic | 72.95% | 77.45% | 79.26% | 61.55% | 47.30% |
| Normalized Basic EPS | 76.66% | 79.56% | 78.58% | 61.08% | 46.88% |
| EPS Diluted | 72.95% | 77.45% | 79.26% | 61.55% | 47.30% |
| Normalized Diluted EPS | 76.66% | 79.56% | 78.58% | 61.08% | 46.88% |
| Average Basic Shares Outstanding | 167.38% | 314.67% | 1,080.69% | 893.58% | 616.56% |
| Average Diluted Shares Outstanding | 167.38% | 314.67% | 1,080.69% | 893.58% | 616.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |